Performance Evaluation of the BD SARS-CoV-2 Reagents for the BD MAX System | Zendy

Karen Yanson | Zendy; William Laviers | Zendy; Lori A. Neely | Zendy; Elizabeth Lockamy | Zendy; Luis Carlos Castillo-Hernandez | Zendy; Christopher Oldfied | Zendy; Ronald Ackerman | Zendy; Jamie Ackerman | Zendy; Daniel A. Ortiz | Zendy; Sixto Pacheco | Zendy; Patricia J. Simner | Zendy; Stephen Young | Zendy; Erin McElvania | Zendy; Charles K. Cooper | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Performance Evaluation of the BD SARS-CoV-2 Reagents for the BD MAX System

Author(s) -

Karen Yanson,

William Laviers,

Lori A. Neely,

Elizabeth Lockamy,

Luis Carlos Castillo-Hernandez,

Christopher Oldfied,

Ronald Ackerman,

Jamie Ackerman,

Daniel A. Ortiz,

Sixto Pacheco,

Patricia J. Simner,

Stephen Young,

Erin McElvania,

Charles K. Cooper

Publication year - 2021

Publication title -

journal of clinical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.349

H-Index - 255

eISSN - 1070-633X

pISSN - 0095-1137

DOI - 10.1128/jcm.01019-21

Subject(s) - covid-19 , nucleic acid amplification tests , virology , medicine , infectious disease (medical specialty) , outbreak , disease , chlamydia trachomatis

Nucleic acid amplification testing (NAAT) for SARS-CoV-2 is the standard approach for confirming COVID-19 cases. This study compared results between two emergency use authorization (EUA) NAATs, with two additional EUA NAATs utilized for discrepant testing.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research